108 related articles for article (PubMed ID: 10418980)
1. Tamoxifen resistant breast cancer: coregulators determine the direction of transcription by antagonist-occupied steroid receptors.
Takimoto GS; Graham JD; Jackson TA; Tung L; Powell RL; Horwitz LD; Horwitz KB
J Steroid Biochem Mol Biol; 1999; 69(1-6):45-50. PubMed ID: 10418980
[TBL] [Abstract][Full Text] [Related]
2. The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT.
Jackson TA; Richer JK; Bain DL; Takimoto GS; Tung L; Horwitz KB
Mol Endocrinol; 1997 Jun; 11(6):693-705. PubMed ID: 9171233
[TBL] [Abstract][Full Text] [Related]
3. Thoughts on tamoxifen resistant breast cancer. Are coregulators the answer or just a red herring?
Graham JD; Bain DL; Richer JK; Jackson TA; Tung L; Horwitz KB
J Steroid Biochem Mol Biol; 2000 Nov; 74(5):255-9. PubMed ID: 11162933
[TBL] [Abstract][Full Text] [Related]
4. Nuclear receptor conformation, coregulators, and tamoxifen-resistant breast cancer.
Graham JD; Bain DL; Richer JK; Jackson TA; Tung L; Horwitz KB
Steroids; 2000; 65(10-11):579-84. PubMed ID: 11108862
[TBL] [Abstract][Full Text] [Related]
5. A nuclear receptor corepressor modulates transcriptional activity of antagonist-occupied steroid hormone receptor.
Zhang X; Jeyakumar M; Petukhov S; Bagchi MK
Mol Endocrinol; 1998 Apr; 12(4):513-24. PubMed ID: 9544987
[TBL] [Abstract][Full Text] [Related]
6. Role of estrogen receptor alpha transcriptional coregulators in tamoxifen resistance in breast cancer.
Girault I; Bièche I; Lidereau R
Maturitas; 2006 Jul; 54(4):342-51. PubMed ID: 16822624
[TBL] [Abstract][Full Text] [Related]
7. Cell cycle progression stimulated by tamoxifen-bound estrogen receptor-alpha and promoter-specific effects in breast cancer cells deficient in N-CoR and SMRT.
Keeton EK; Brown M
Mol Endocrinol; 2005 Jun; 19(6):1543-54. PubMed ID: 15802375
[TBL] [Abstract][Full Text] [Related]
8. Expression of nuclear receptor interacting proteins TIF-1, SUG-1, receptor interacting protein 140, and corepressor SMRT in tamoxifen-resistant breast cancer.
Chan CM; Lykkesfeldt AE; Parker MG; Dowsett M
Clin Cancer Res; 1999 Nov; 5(11):3460-7. PubMed ID: 10589759
[TBL] [Abstract][Full Text] [Related]
9. Steroid hormone receptors and coregulators in endocrine-resistant and estrogen-independent breast cancer cells.
Sarvilinna N; Eronen H; Miettinen S; Vienonen A; Ylikomi T
Int J Cancer; 2006 Feb; 118(4):832-40. PubMed ID: 16152593
[TBL] [Abstract][Full Text] [Related]
10. Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action.
Shibata H; Spencer TE; Oñate SA; Jenster G; Tsai SY; Tsai MJ; O'Malley BW
Recent Prog Horm Res; 1997; 52():141-64; discussion 164-5. PubMed ID: 9238851
[TBL] [Abstract][Full Text] [Related]
11. Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.
Hoffmann J; Sommer A
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):191-200. PubMed ID: 15860262
[TBL] [Abstract][Full Text] [Related]
12. Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen.
Girault I; Lerebours F; Amarir S; Tozlu S; Tubiana-Hulin M; Lidereau R; Bièche I
Clin Cancer Res; 2003 Apr; 9(4):1259-66. PubMed ID: 12684393
[TBL] [Abstract][Full Text] [Related]
13. The corepressors silencing mediator of retinoid and thyroid hormone receptor and nuclear receptor corepressor are involved in agonist- and antagonist-regulated transcription by androgen receptor.
Yoon HG; Wong J
Mol Endocrinol; 2006 May; 20(5):1048-60. PubMed ID: 16373395
[TBL] [Abstract][Full Text] [Related]
14. Dominant-negative nuclear receptor corepressor relieves transcriptional inhibition of retinoic acid receptor but does not alter the agonist/antagonist activities of the tamoxifen-bound estrogen receptor.
Morrison AJ; Herrera RE; Heinsohn EC; Schiff R; Osborne CK
Mol Endocrinol; 2003 Aug; 17(8):1543-54. PubMed ID: 12730327
[TBL] [Abstract][Full Text] [Related]
15. OCT-4: a novel estrogen receptor-α collaborator that promotes tamoxifen resistance in breast cancer cells.
Bhatt S; Stender JD; Joshi S; Wu G; Katzenellenbogen BS
Oncogene; 2016 Nov; 35(44):5722-5734. PubMed ID: 27065334
[TBL] [Abstract][Full Text] [Related]
16. Tamoxifen through GPER upregulates aromatase expression: a novel mechanism sustaining tamoxifen-resistant breast cancer cell growth.
Catalano S; Giordano C; Panza S; Chemi F; Bonofiglio D; Lanzino M; Rizza P; Romeo F; Fuqua SA; Maggiolini M; Andò S; Barone I
Breast Cancer Res Treat; 2014 Jul; 146(2):273-85. PubMed ID: 24928526
[TBL] [Abstract][Full Text] [Related]
17. New vs old fashioned oestradiol antagonists in mammary carcinoma: 'in vitro' and 'in vivo' pharmacological approaches.
de Cupis A; Schettini G; Favoni RE
Pharmacol Res; 1999 May; 39(5):335-44. PubMed ID: 10328990
[TBL] [Abstract][Full Text] [Related]
18. Characterization of new estrogen receptor destabilizing compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancer.
Hoffmann J; Bohlmann R; Heinrich N; Hofmeister H; Kroll J; Künzer H; Lichtner RB; Nishino Y; Parczyk K; Sauer G; Gieschen H; Ulbrich HF; Schneider MR
J Natl Cancer Inst; 2004 Feb; 96(3):210-8. PubMed ID: 14759988
[TBL] [Abstract][Full Text] [Related]
19. Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo.
Schiff R; Reddy P; Ahotupa M; Coronado-Heinsohn E; Grim M; Hilsenbeck SG; Lawrence R; Deneke S; Herrera R; Chamness GC; Fuqua SA; Brown PH; Osborne CK
J Natl Cancer Inst; 2000 Dec; 92(23):1926-34. PubMed ID: 11106684
[TBL] [Abstract][Full Text] [Related]
20. A new strategy for selective targeting of progesterone receptor with passive antagonists.
Khan JA; Tikad A; Fay M; Hamze A; Fagart J; Chabbert-Buffet N; Meduri G; Amazit L; Brion JD; Alami M; Lombès M; Loosfelt H; Rafestin-Oblin ME
Mol Endocrinol; 2013 Jun; 27(6):909-24. PubMed ID: 23579486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
